BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://www.europabio.org X-WR-CALDESC:Events for Europabio REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Europe/Brussels BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20200329T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20201025T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20210328T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20211031T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20220327T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20221030T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20230326T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20231029T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20240331T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20241027T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20231201T083000 DTEND;TZID=Europe/Brussels:20231201T094500 DTSTAMP:20260726T174257 CREATED:20231031T084455Z LAST-MODIFIED:20231031T084520Z UID:7041-1701419400-1701423900@www.europabio.org SUMMARY:EFIB 2023 Rotterdam Statement wider launch DESCRIPTION:Industrial biotechnology for a sustainable and resilient global Europe  \n\n\n\nAs the EU looks ahead to the European elections in 2024\, with a new EU Commission mandate and Work Programme\, EuropaBio reviews European strategies and ambitions where biotechnology plays a key role. Ursula von der Leyen’s State of the European Union address of 13 September announced an ‘EU Biotech and Biomanufacturing Initiative’. The announced EU initiative is the latest indication of a greater point of recognition and acceleration for biotechnology. \n\n\n\nBuilding on this momentum\, the EFIB Rotterdam Statement of 2023 provides a priority pathway for biotechnology to support Europe’s global leadership\, resilience and competitiveness. \n\n\n\nWe invite you to join us for a discussion on the role and potential of biotechnology and Europe’s global position in the context of the 2024 EU election. \n\n\n\n\nInvitation Only Event URL:https://www.europabio.org/event/efib-2023-rotterdam-statement-wider-launch/ CATEGORIES:EFIB,EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Vilnius-Statement-Event-600-×-260px.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20231130T143000 DTEND;TZID=Europe/Brussels:20231130T160000 DTSTAMP:20260726T174257 CREATED:20231018T092656Z LAST-MODIFIED:20231018T113625Z UID:7003-1701354600-1701360000@www.europabio.org SUMMARY:EuropaBio Patient BioForum 2023 Roundtable on Advancing Solutions for Unmet Medical Needs DESCRIPTION:Hybrid Event | Invitation Only \n\n\n\n\n\nEuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. To address unmet medical needs (UMN)\, the Commission proposed as part of the revision of the EU General Pharmaceutical Legislation (GPL) to introduce a definition of UMN and a definition of high UMN. Under the Commission’s proposals\, all orphan products would qualify as addressing UMN but only a subset of products would meet the HUMN criteria. The Commission’s proposals on UMN and especially HUMN received mixed reactions from patient organisations and negative reactions from the industry. \n\n\n\nOn 1 December 2022\, EuropaBio organised a Patient BioForum which brought together industry and patient organisations to discuss the topic of UMN in view of reaching a common understanding on UMN. Those discussions revealed shared interests and concerns with the possible approach to UMN in the EU Pharmaceutical Legislation. The discussions were followed by a report which outlined recommendations to policymakers to enable Europe to address the challenge of UMN. \n\n\n\nWith the proposals now presented and being negotiated by the European Parliament and the Council\, the 2023 Patient BioForum is an opportunity to build on the 2022 Patient BioForum to foster exchanges between patient groups and industry on UMNs\, including expectations from the legislation and beyond. The 2023 Patient BioForum will also be an opportunity to issue multi-stakeholder recommendations to policymakers to ensure the GPL is fit for purpose to address patients need and support innovation.   \n\n\n\n \n\n\n\nProgramme \n\n\n\nThe 2023 Patient BioForum will be held in a roundtable format under Chatham House Rule. A wide range of stakeholders representing patients\, regulators\, policy-makers\, and industry will be invited to take part in the roundtable. All participants will be invited to take an active part in the discussion to bring their unique perspective. The roundtable will be followed by a report to summarise the discussions. \n\n\n\n1. Introductions \n\n\n\n2. Legislating Unmet Medical Needs: Perspectives from the European Commission and the European Parliament \n\n\n\n3. Roundtable topic 1: How Can the EU Pharmaceutical Legislation Help Stimulate Patient-Centric Innovation? \n\n\n\n4. Roundtable topic 2: How can Europe Incentivise R&D for UMN and Underserved Areas? \n\n\n\n5. Conclusions \n\n\n\nIf you would like to attend\, please contact Adrian Lincoln\, a.lincoln@europabio.org URL:https://www.europabio.org/event/europabio-patient-bioforum-2023-roundtable-on-advancing-solutions-for-unmet-medical-needs/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/10/Event-Banners-Website-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20231024T080000 DTEND;TZID=Europe/Brussels:20231025T170000 DTSTAMP:20260726T174257 CREATED:20230413T124141Z LAST-MODIFIED:20230525T155522Z UID:6110-1698134400-1698253200@www.europabio.org SUMMARY:EFIB 2023 - Industrial biotechnology for a sustainable and resilient global Europe DESCRIPTION:EuropaBio is pleased to announce that this year’s edition of EFIB\, Europe’s Leading Event on Industrial Biotechnology and the Bioeconomy under the title ‘Industrial biotechnology for a sustainable and resilient global Europe’\, will take place 24-25 October 2023 in Rotterdam\, The Netherlands. EuropaBio is partnering with local hosts HollandBio and ChemistryNL to bring EFIB 2023 to Rotterdam. \n\n\n\nNow in its 16th year\, EFIB will be dedicated to exploring how industrial biotechnology and the bioeconomy supports European competitiveness. EFIB brings together professionals from across the value chain to discuss advancements from industrial biotechnology and its contribution towards positioning Europe as a global leader in addressing societal and sustainability challenges. Participants include industry of all sizes\, as well as the community that enables industry to deliver\, including researchers\, policy makers\, regulators\, and global organisations. \n\n\n\nOur two-day programme includes inspiring plenaries\, a start-up pitching hour and will explore our four thematic areas – Food\, Feed & Nutrition; Sustainable Biomaterials; Bioprocesses & Technologies; and Sustainable Finance – as well as new frontiers like biomanufacturing. The programme is complemented by the exhibition: including start-ups and SMEs in our SME Village\, the academic poster presentation in our Innovation Campus\, and exhibitors from industry and national associations. Interested in exhibiting? Check out our sponsorship page.   \n\n\n\nAttending EFIB 2023 will allow you to learn about the latest market trends and research findings in industrial biotechnology and network with key stakeholders. \n\n\n\n\nRegister Here\n\n\n\n\nFor more information visit our website and subscribe to our newsletter. URL:https://www.europabio.org/event/efib-2023-industrial-biotechnology-for-a-sustainable-and-resilient-global-europe/ CATEGORIES:EFIB ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/04/Copy-of-General-template-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20231011T133000 DTEND;TZID=Europe/Brussels:20231011T150000 DTSTAMP:20260726T174257 CREATED:20230920T110911Z LAST-MODIFIED:20230920T110912Z UID:6861-1697031000-1697036400@www.europabio.org SUMMARY:SMEs in a Changing World: The Impact of the Revision of the Pharmaceutical Legislation on Europe’s innovative SMEs DESCRIPTION:In April 2023\, the European Commission published new legislative proposals to revise the EU’s long-standing pharmaceutical legislation and ensure it can meet the challenges of the 21st century. The revision will redefine the regulatory framework for medicines and have a significant impact on the global innovation ecosystem. \n\n\n\nAs emerging and small companies have become innovation drivers\, responsible for over two-thirds of the R&D pipeline that will become the medicines of tomorrow\, changing the rule book that has helped build Europe’s small company ecosystem over the last 20 years is going to have consequences for start-ups\, emerging and small companies looking to first enter the market but also on mid-size companies looking for growth opportunities in Europe. \n\n\n\nThis event will be an opportunity to highlight the role of small and mid-size companies in developing medicines for patients\, assess the foreseeable impacts of the revision on those companies\, and hear directly from them what they need from the revision to continue their journey in Europe. URL:https://www.europabio.org/event/smes-in-a-changing-world-the-impact-of-the-revision-of-the-pharmaceutical-legislation-on-europes-innovative-smes/ CATEGORIES:EuropaBio,External,Healthcare Biotech,SME Platform ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/09/Event-Banners-Website.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230627T180000 DTEND;TZID=Europe/Brussels:20230627T200000 DTSTAMP:20260726T174257 CREATED:20230524T142640Z LAST-MODIFIED:20230616T172415Z UID:6330-1687888800-1687896000@www.europabio.org SUMMARY:NAC Spanish Presidency Summer Reception DESCRIPTION:EuropaBio\, and AseBio\, the Spanish Association of Biotechnology Companies\, with the support of Merck\, will host a summer reception to mark the beginning of the Spanish Council Presidency of the European Union and present the outcomes of their National Association Council Presidency Summit.  \n\n\n\nThe event will take place on June 27th in Brussels at Comet Meetings – Louise\, from 18-20h. If you wish for more details\, please get in touch with José Peres at j.peres@europabio.org  URL:https://www.europabio.org/event/nac-spanish-presidency-summer-reception/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/NAC-Summer-Reception-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230605T173000 DTEND;TZID=Europe/Brussels:20230605T183000 DTSTAMP:20260726T174257 CREATED:20230523T115247Z LAST-MODIFIED:20230524T142835Z UID:6282-1685986200-1685989800@www.europabio.org SUMMARY:EuropaBio: BIO 2023 DESCRIPTION:Round table –Biomanufacturing for health: advancing healthcare and global preparedness \n\n\n\n\n\nEuropaBio is pleased to host a round table discussion at the upcoming BIO International Convention in Boston and invites all delegates to join us to discuss on biomanufacturing for health: advancing healthcare and global prepareness. \n\n\n\nBiomanufacturing within healthcare represents an advance in therapeutic capabilities\, as ground-breaking research translates into increased diseases that can be targeted\, either for the first time or with greater efficacy\, with increasingly complex interventions becoming possible. It also brings resilience and increased environmental sustainability to strained supply chains as the world strives to modernise production systems. \n\n\n\nThe transition has significant implications for global healthcare\, competitiveness\, sustainability and resilience\, with capacity building important in all regions. \n\n\n\nThis is not just reflected in advancing healthcare for citizens but also for the world’s ability to respond to healthcare crises.  Covid demonstrated that  biomanufacturing capacity globally was called into action from multiple applications and countries for the complex manufacturing process behind vaccines. \n\n\n\nThis biomanufacturing capacity does not exist within a vacuum\, ready to be called to action when needed. It requires drug developers large and small\, public and private\, specialised manufacturers\, plus skills base\, supply chain and logistics frameworks resulting from significant investment over many years. \n\n\n\nImportantly\, a sustainable biomanufacturing framework is financed and delivered primarily through industry\, meaning that is must be integral to company strategy. This is not a guarantee\, as the global healthcare industry reacts to legislative changes and government strategies\, with major investment decisions having long term implications for the capacity and skills base within countries and regions. \n\n\n\nWhat does the world need to get right to ensure that biomanufacturing capacity grows\, to serve patients with advancing therapies and be there for coordinated emergency responses? \n\n\n\nParticipants within the round table reflect global biomanufacturing stakeholders and will discuss: \n\n\n\n\nNational policies\, incentives and strategy\n\n\n\nRegulatory and standards and alignment\n\n\n\nInternational cooperation and development\n\n\n\n\nThe output from this roundtable will be a call to global action for biomanufacturing published through EuropaBio and BIO\, with all delegates invited to contribute through the round table and follow up. \n\n\n\nAgenda \n\n\n\n10:30Welcome and introductionEuropaBio and BIO10:40Setting the scene for global biomanufacturing and the planned outcome from the round tableClaire10:45(draft) Discussion points for participants: – What does your country need to achieve for resilience through national or accessible biomanufacturing capacity?– How are regulatory frameworks adapting to an increasingly biological pipeline of medicines?– What does international cooperation need to achieve to ensure that manufacturing is actually possible during pandemic responses?– Name a priority for you to reach biomanufacturing goals in the coming years.All participants: Lead interventions on specific topics11:30Closing remarksEuropaBio and BIO\n\n\n\n\n\n\n\n \n\n\n\n\nMore information here URL:https://www.europabio.org/event/europabio-bio-2023/ LOCATION:Boston Convention & Exhibition Center\, Boston\, Massachusetts\, United States CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2023/05/Event-Banners-Website.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230427T140000 DTEND;TZID=Europe/Brussels:20230427T151500 DTSTAMP:20260726T174257 CREATED:20230322T114230Z LAST-MODIFIED:20230412T135959Z UID:6092-1682604000-1682608500@www.europabio.org SUMMARY:EuropaBio Biomanufacturing Policy Summit 2023: Where next for Europe? DESCRIPTION:Summit outcomes and next steps \n\n\n\n\n\nOn 15th March\, EuropaBio hosted its first Biomanufacturing Policy Summit in Brussels\, with the aim of setting the vision for Europe’s global innovation\, competitiveness\, and sustainability on biomanufacturing\, while raising awareness among policy-makers. The Summit established a starting point\, a first step for a long journey that needs to be traveled by all stakeholders in Europe – SMEs\, large companies\, expert services\, and EU institutions – and which has already started in other parts of the world. \n\n\n\n80 attendees from industry\, national associations\, and stakeholders across the public and private spectrum presented\, debated\, and proposed.  In a fast-moving industrial transition\, calls for visionary policies\, enabling regulation\, and urgent action were some of the key takeaways from the summit. You can see the March 15th Summit agenda here. \n\n\n\nWould you like to find out more? \n\n\n\nJoin us on April 27 between 14:00 – 15:15 CET for a summit presentation and follow-up and add your voice to the discussion. This webinar will wrap up the main outcomes of the summit and lay the groundwork for future discussions. \n\n\n\nBiomanufacturing is key to the digital and green transitions and to securing a competitive and resilient future for Europe. Stay tuned for Europe’s future in biomanufacturing! \n\n\n\nAGENDA\n\n\n\n14:00: Welcome and introduction – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n14:10: Biomanufacturing Policy Summit report presentation – Virginia Claudio\, Sr Adviser & Programme Manager\, EuropaBio \n\n\n\nThe report presentation summarises the summit outcomes and builds policy recommendations for the development of the Biomanufacturing landscape in Europe. \n\n\n\n14:20: Report perspectives & reflections from healthcare and biotech industries\, and national associations – Sarah Moundir\, EU Public Affairs Senior Manager\, Novartis | Gwenael Servant\, Board Executive\, Abolis | Inga Matijosyte\, Vice President\, LithuaniaBIO \n\n\n\nA diverse group of stakeholders representing the wide spectrum of Biomanufacturing shares their views over the report outcomes\, as well as the priorities for their companies and organisations. \n\n\n\n14:50: Discussion and Q&A with the audience \n\n\n\nA discussion based on questions from the audience with a focus on the next steps for policy making on Biomanufacturing. \n\n\n\n15:10: Close – Closing remarks. \n\n\n\n\n\n\nRegister Here URL:https://www.europabio.org/event/europabio-biomanufacturing-policy-summit-2023-where-next-for-europe/ CATEGORIES:Biomanufacturing Platform,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/03/SM1-Quotes-Key-Messages-600-×-200px-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230418T150000 DTEND;TZID=Europe/Brussels:20230418T160000 DTSTAMP:20260726T174257 CREATED:20230124T170639Z LAST-MODIFIED:20230406T134218Z UID:5708-1681830000-1681833600@www.europabio.org SUMMARY:Development of Orphan Biologics: Challenges and Opportunities DESCRIPTION:Webinar sponsored by Catalent \n\n\n\n\n\n\n\n\n\nThe development of therapies for rare diseases comes with distinct challenges\, including patient recruitment\, setting meaningful clinical endpoints\, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy. \n\n\n\nFor biologic products (growth factors\, monoclonal antibodies\, other complex proteins)\, development and production costs tend to be higher due to the complexity of the drug substance. To manage costs\, the clinical development and manufacturing and Chemistry\, Manufacturing and Controls (CMC) teams need to be aligned to ensure drug product is delivered on time to meet clinical trial needs. \n\n\n\nThese challenges sit within a wider regulatory and legislative framework for orphan medicinal products (OMPs) that defines whether companies can successfully develop a novel product to market and thus the decisions made for selecting therapeutics and target diseases early in development. \n\n\n\nDuring this webinar\, speakers cover aspects of clinical trial design for orphan biologics products\, key strategies for ensuring clinical trial supply throughout clinical development and the regulatory and legislative framework for delivery to patients.Key Learning Objectives \n\n\n\n\nConsiderations in identifying meaningful clinical endpoints for orphan diseases\n\n\n\nOrphan clinical trial design considerations and strategies to ensure sufficient patient recruitment\n\n\n\nManufacturing and clinical supply strategies to ensure supply of clinical trial materials while collecting data needed to support NDA submission\n\n\n\nRegulatory and legislative frameworks that guide decision making for innovation in rare diseases\n\n\n\n\nAgenda \n\n\n\n15:00: Welcome and introduction – Claire Skentelbery\, Director General EuropaBio \n\n\n\n15:05: Current Development of Orphan Drugs in Europe – Matthias Schoenermark\, Professor\, President and CEO\, SKC Beratungsgesellschaft mbH \n\n\n\nProf. Schönermark opens the session with an overview of the current status of orphan drug development in the EU. He discusses the main challenges for market entry of new orphan drugs into the EU market and highlights key recommendations to drug developers to address these challenges. \n\n\n\n15:20: Orphan Biologics and CGT Development – CMC and Clinical Trial Supply Considerations – Wai Lam Ling\, Ph.D.\, Vice President\, Science and Technology\,  Catalent \n\n\n\nDr. Ling discusses the difference in CMC challenges encountered during an orphan biologics vs CGT programme\, with a focus on product quality as the most significant hurdle to approval. She addresses manufacturing approaches to ensure regulatory compliance and factors behind a successful product\, particularly robust\, reproducible and cost-effective pathways. Finally\, supply chain liabilities are discussed\, with risks to production of biologics and their clinical supply. \n\n\n\n15:45: Successful Strategies and Business Model For Companies Bringing Their Orphan Drug To Market –Thomas Bols\, Head of Government Affairs and Patient Advocacy\, EMEA & APAC\, PTC Therapeutics \n\n\n\nThomas Bols addresses the spectrum of opportunities and barriers for innovation within orphan drug development\, particularly across different regulatory territories\, and the critical role of smaller companies in addressing unmet medical needs. He focuses on the legislative and regulatory pathways that exist in Europe for orphan drugs and the potential impact of the upcoming pharmaceutical and OMP legislation revisions for company innovation and patient benefits. \n\n\n\n16:00: Close \n\n\n\n\nRegister here URL:https://www.europabio.org/event/development-of-orphan-biologics-challenges-and-opportunities/ LOCATION:Catalent CATEGORIES:EuropaBio,External,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2023/01/Biomanufacturing-Policy-Summit-2023-5.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20230315T130000 DTEND;TZID=Europe/Brussels:20230315T190000 DTSTAMP:20260726T174257 CREATED:20221114T094047Z LAST-MODIFIED:20230308T114450Z UID:5505-1678885200-1678906800@www.europabio.org SUMMARY:Biomanufacturing Platform - Policy Summit 2023 DESCRIPTION:EuropaBio’s first Biomanufacturing Policy Summit will set the vision for Europe’s global innovation\, competitiveness and sustainability through the lens of biomanufacturing and set a baseline for its understanding and recognition within policy. \n\n\n\nThe half day meeting will bring together Members and invited stakeholders from across the policy\, finance\, trade\, skills and regulatory spectrum surrounding biomanufacturing. \n\n\n\nDiscussion will address what biomanufacturing looks like across sectors and the roles played by SMEs\, large companies and expert services. The economic and skills footprint will be reviewed\, plus how it sits within Europe’s twin pillars of green and digital transition within the industrial strategy. Finally\, it can start to address how policy shapes and facilitates biomanufacture and Europe’s global position for such a transformative technology in action. \n\n\n\nFrom the first Summit\, a roadmap for biomanufacture can be developed for Europe and creation of a long term discussion platform for stakeholders through the Platform. \n\n\n\nAgenda \n\n\n\n14:00Opening plenary14:00Welcome and introduction to the Biomanufacturing Policy Summit– Claire Skentelbery\, Director General\, EuropaBio14:10Biomanufacturing in Europe’s industrial transition– Peter Dröll\, Director Prosperity\, European Commission\, DG Research and Innovation14:30Biomanufacturing as a global transition: US Executive Order for Biomanufacturing in focus– Hilary Stiss\, Director\, International Affairs\, Biotechnology Innovation Organization (BIO) 14:45Quo vadis European Biomanufacturing innovation in a competitive\, globalized world– Wojciech Nowak\, Global Senior Director\, Novartis15:00I am Biomanufacturing: examples in action ● Resilience\, sustainability and competitiveness: Biomanufacturing in daily life: Ute Schick\, Senior Vice President Research\, Development and Innovation (RDI)\, Nutrition & Care (NC-RDI)\, Evonik Operations GmbH ● Growing SMEs: Biomanufacturing in the next generation of industry: Jeroen Hofenk\, Founder and Chief Science Officer\, SwiftPharma ● The national landscape: Belgium’s economic development through biomanufacturing: Tineke Van hooland\, Deputy Secretary General Bio.be ● Advanced healthcare: The role of biomanufacturing in reaching rare diseases: Philippe Moyen\, VP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics15:30Break16:00Parallel Breakout discussionsBreakout 1 – Advanced healthcare: Role and growth in Europe● Role in Europe’s pandemic response. Scale and flexibility of manufacture – planning\, delivering\, investment● Patient access to advanced therapies (including rare diseases).● Competitiveness and economic contributor across EuropeBreakout 2 – Resilience\, competitiveness and sustainability:● Transition of industrial process for sustainability● Building resilience of supply● Innovation for competitiveness17:10Closing plenaryClosing panel discussion: Europe’s ambition and pathway for biomanufacturingStakeholders from across the biomanufacturing landscape look at the future for Europe within biomanufacturing. The industrial goals it must achieve\, the pathway towards those goals and how it can make use of the skills\, infrastructure and policy/regulatory frameworks through which Europe develops.Moderator: Kristin Schreiber (Director DG GROW)Panelists: Peter Wehrheim (Head of Unit RTD.B2)\, Kristin Thompson (COO EUREKARE)\, Nessa Fennelly (Senior Executive IBEC)\, Nicolo Giacomuzzi-Moore (Executive Director CBE JU)\, Stefaan Fiers (Head of Corporate Communication\, Public Affairs and Patient Advocacy Takeda Belgium).18:00Networking reception19:00Close\n\n\n\n \n\n\n\nSpeakers \n\n\n\n\n\n\n\n\n\n\nHilary Stiss\n\n\n\nDirector\, International Affairs\, BIO Program Director\, ICBA \n\n\n\nAs a Director for International Affairs at the Biotechnology Innovation Organization (BIO)\, Hilary is responsible for managing the industry association’s program of international advocacy and outreach for multilateral organizations. Hilary also manages the association’s engagement in Europe\, the Middle East\, North Africa\, Turkey and South Africa regions. In this position\, she engages with foreign officials in these regions to promote policies that support a strong biotechnology industry as well as to resolve policy issues relevant to the industry. Hilary also acts as Program Director for the International Council on Biotechnology Associations (ICBA). \n\n\n\n\n\n\n\n\n\n\n\n\n\nClaire Skentelbery\n\n\n\nClaire holds a PhD in biochemistry and has worked in the development of scientific networks and associations for over 15 years. She started her career as part of the Cambridge biotech cluster in the UK within the cluster business network and was a founder of the Council of European BioRegions\, a network of biotech clusters across Europe. She brought herself and CEBR to Brussels in 2009 where she also took on the role of SG for the European Biotechnology Network\, working across sectors\, organisations and countries as part of the EBN mission to facilitate partnerships. In January 2017\, Claire took up her role as DG of the Nanotechnology Industries Association which she successfully led until recently. \n\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Ute Schick\n\n\n\nSenior Vice President Research\, Development and Innovation\, Evonik \n\n\n\nDr. Schick has a 20-year track record in global profit and loss responsibility at CEO and Senior Manager level within Food\, Health\, Cosmetic Industry and Material Science. Before her current role with Evonik\, she held roles as SVP of Supply Chain and Business Processes and VP of new Growth Business. Prior to working at Evonik she held roles at DuPont and DSM. \n\n\n\n\n\n\n\n\n\n\n\n\n\nWojciech Nowak\n\n\n\nGroup Senior Director\, Global Governmental and Public Affairs\, Novartis International\, Switzerland.(Functional responsibility for ca. 30 countries incl. Western & Eastern Europe\, Central Asia). \n\n\n\nMulticultural\, inclusive and reflective leader who lived in 6 countries on 3 continents.Robust understanding of the global healthcare policies and life-sciences business with more than 20 years of experience in policy creation related to healthcare systems\, EU integration and global pharmaceutical market. \n\n\n\nStarted his career at the Ministry of Health (Poland) counselling policy leaders on European integration and healthcare matters\, followed by assignments in the Ministry of Health and Solidarity of the Republic of France (Paris\, France) and Health Directorate of the European Commission (DG SANCO\, Luxembourg). \n\n\n\nAfter joining private sector has been serving in a number of senior leadership roles of growingresponsibility in healthcare companies(GlaxoSmithKline\, Abbott\, Novartis) on country\, regional and global levels (Poland\, Belgium\, Switzerland). \n\n\n\nEducated in Poland\, United States\, Nederlands\, Switzerland\, with the background in political sciences\, international relations (Warsaw’s University\, Poland; European Institute of Public Administration\, Maastricht\, Nederlands) and business administration (IMD Business School Lausanne\, Switzerland) he is an expert in healthcare systems\, global healthcare policies and international business. \n\n\n\nPassionate about delivering access and best healthcare outcomes to patients around the World. \n\n\n\n\n\n\n\n\n\n\n\n\n\nTineke Van Hooland\n\n\n\nDeputy Secretary general of bio.be/essenscia \n\n\n\nTineke Van Hooland is Deputy Secretary general of bio.be/essenscia\, the Belgian federation of companies active in life sciences & biotechnologies. She’s also a board member at EuropaBio\, the European Association for Bioindustries\, from which she also chairs the NAC\, National Associations Council. Prior to this\, Tineke held several leadership positions in biopharmaceutical companies at the corporate level over the past years. She has in-depth expertise in Governmental Affairs\, Market Access\, Communication and Patient Advocacy. Tineke graduated with High Distinction as Industrial Pharmacist from Ghent University in 2003. \n\n\n\nTineke is also the founder and CEO of epic 10\, a boutique external affairs consultancy firm\, and a respected board member in various other organizations.  She is known for her dynamic and no-nonsense approach\, is a female leadership advocate and has authored a number of opinion pieces on sustainable health policy and empowering women. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Schreiber\n\n\n\nKristin Schreiber leads the Directorate Ecosystems I: Chemicals\, Food\, Retail\, Health in DG GROW\, the Directorate General for Internal Market\, Industry\, Entrepreneurship and SMEs. \n\n\n\nPrior to her current Director position\, she served as Director for Governance of the Single Market and International Affairs in DG MARKT (until 2015) and Director for SME policy in DG GROW (until March 2021). \n\n\n\nKristin Schreiber was Head of Cabinet of Employment Commissioner Vladimir Špidla\, Deputy Head of Cabinet of Internal Market Commissioner Michel Barnier and member of the Cabinets of Enlargement Commissioner Günter Verheugen and Competition Commissioner Karel Van Miert. She also served as Head of Unit for International Affairs in DG Employment and Social Affairs and was a member of the Merger Task Force of DG Competition. \n\n\n\n\n\n\n\n\n\n\n\n\n\nStefaan Fiers\n\n\n\nCorporate Communications\, Public Affairs and Patient Advocacy Takeda \n\n\n\nStefaan is Head of Corporate Communications\, Public Affairs and Patient Advocacy at Takeda Belgium\, one of the largest pharmaceutical companies in Belgium. With his team\, he secures the healthcare policy analysis\, engages with external stakeholders and coordinates the company’s communication strategy. Additionally\, he oversees Takeda’s public affairs activities in 24 mid-sized European countries. \n\n\n\nBefore joining Takeda in June 2020\, he was Director of Communications and Public Policy at the Belgian pharma industry association pharma.be and held public policy positions in the pharma industry\, at Bristol-Myers Squibb Belgium/Luxembourg and at MSD Belgium.Next to his activities at Takeda\, Stefaan is an Associate Professor in Public Affairs and Comparative Politics at KU Leuven\, a Board member of PACE (Public Affairs Community Europe)\, and the author of several books and peer-reviewed articles. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPhilippe Moyen\n\n\n\nVP\, Chief of Staff to CTOO and Head of CMC Program Management – Technical Operations\, PTC Therapeutics \n\n\n\nFollowing a university focus on therapeutic systems\, followed by formulation and industrial development\, Philippe has worked across the biotechnology spectrum including Baxter Healthcare\, Fresenius Kabi\, Stallergenes Greer\, and PTC Therapeutics where he has a strong focus on operations. \n\n\n\n\n\n\n\n\n\n\n\n\n\nKristin Thompson\n\n\n\nVP\, Chief Business Officer \n\n\n\nKristin Thompson is a former head of strategic partnerships in microbiomes at Bioaster. Before that\, Dr. Thompson was senior BD manager at Famar and BD manager of the French biotech company DaVolterra. She worked in research at French INSERM and the University of North Carolina\, Chapel Hill. She holds a Ph.D. in molecular biology from the University of Ulm\, Germany. \n\n\n\n\n\n\n\n\n\n\n\n\n\nNicoló Giacomuzzi-Moore\n\n\n\nExecutive Director ad interim\, Circular Bio-based Industries Joint Undertaking \n\n\n\nNicoló Giacomuzzi-Moore is CBE JU’s Executive Director ad interim and Head of the Administration and Finance Unit. He has been working in European affairs for more than 20 years\, focusing on research and innovation policy\, program implementation\, and enterprise support. \n\n\n\nBefore joining BBI JU (now CBE JU) in 2016\, he worked for the European Commission’s Research Executive Agency\, where he was responsible for financial and legal support in implementing European research projects. \n\n\n\nNicoló also worked for an Italian business association dealing with industrial policy and stakeholder management at the EU level. He holds a degree in economics and international trade. \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Dröll\n\n\n\nDirector for Prosperity\, Directorate-General for Research and Innovation \n\n\n\nPeter Dröll has been working in the European Commission for more than 20 years with positions in the environment\, enlargement negotiations\, industry policy\, innovation\, and research. He was a Cabinet member of Enlargement Commissioner Günter Verheugen and Head of Cabinet of the Science and Research Commissioner Janez Potočnik. \n\n\n\nSince 2010 he is at the Directorate-General of Research and Innovation where he was first responsible for Innovation and then for Industrial Technologies. Following the re-orientation of DG Research and Innovation towards sustainability\, his competencies have been enlarged to include industrial R&I agendas and business intelligence as well as knowledge valorization policies. \n\n\n\nBefore joining the European Commission in 1991\, Peter worked as a lawyer in a German law firm. Peter is a lawyer by training with a doctorate degree in German constitutional law and European law. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJeroen Hofenk\n\n\n\nFounder and Chief Science Officer\, SwiftPharma \n\n\n\nJeroen is a serial entrepreneur and scientist with a background in bioengineering and genetics. He has broad experience in CRISPR engineering and various expression platforms including microbial-\, animal cell-based\, and plants.  In the last 10 years of his career\, Jeroen has built a strong track record in plant-made-pharmaceutical manufacturing and the optimization thereof. He obtained 3 patent grants and holds 13 pending patents to his name.” \n\n\n\n\n\n\n\n\n\n\n\n\n\nPeter Wehrheim\n\n\n\nHead of the Unit for the “Bioeconomy and Food System” within the Directorate General for Research and Innovation of the European Commission in Brussels \n\n\n\nWhile working for Phil Hogan\, Commissioner for Agriculture and Rural Development\, he contributed to the EU Bioeconomy Strategy. From 2010 to 2018 he was Head of the Unit for Land Use and Climate Finance in DG Climate Action. Before 2004 Peter worked at the Universities of Bonn/DE\, Maryland/US (with a Heisenberg scholarship from the German Research Foundation)\, and Kiel/DE. He received his doctoral degree in agricultural economics from the University of Giessen\, Germany \n\n\n\n\n\n\nAbout the EuropaBio Biomanufacturing Platform \n\n\n\nThe Platform has the mission to represent biomanufacturing at the highest policy levels in Europe\, to ensure that it is visible and recognised within the industrial strategy and Europe’s green and digital transitions. \n\n\n\nEuropaBio’s Biomanufacturing Platform will address the policy and wider frameworks through which biomanufacturing is delivered.  Together with members and stakeholders\, it will address how economic growth\, employment and resilience are achieved through policy\, legal frameworks and regulation at EU and national levels. \n\n\n\nThe Summit will be open to EuropaBio Members and invited stakeholders. Please contact c.skentelbery@europabio.org for further information. URL:https://www.europabio.org/event/biomanufacturing-platform-policy-summit-2023/ LOCATION:BIP Meeting Center – House of the Capital Region\, rue Royale 2-4\, Brussels\, 1000\, Belgium CATEGORIES:Biomanufacturing Platform,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/SM1-Quotes-Key-Messages-600-×-200px.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221201T143000 DTEND;TZID=Europe/Brussels:20221201T160000 DTSTAMP:20260726T174257 CREATED:20221117T151753Z LAST-MODIFIED:20221121T110237Z UID:5532-1669905000-1669910400@www.europabio.org SUMMARY:EuropaBio Patient BioForum 2022: Toward a Common Understanding of Unmet Medical Needs DESCRIPTION:EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific\, regulatory\, and policy issues between patient organisations and the biopharmaceutical industry. \n\n\n\nIn recent years\, unmet medical needs have been at the core of Europe’s pharmaceutical and public health policies. Addressing unmet medical need was outline as a central to the 2020 Pharmaceutical Strategy for Europe. One perceived shortcoming of the current legislative frameworks is insufficient stimulated development in some areas of ‘unmet medical need’ (UMN) such as antimicrobial resistance or rare diseases. The upcoming revision of the EU pharmaceutical legislation and orphan and paediatric legislation will aim at addressing “unmet medical needs”. \n\n\n\nA major hurdle to overcome is reaching a common understanding of unmet medical needs as stakeholders have different understanding of the concept based on different perceptions and expectations. Unmet medical need is scientific concept which can be used to identify patient and societal health needs and stimulate research activities. As science progresses\, and with it the knowledge to address unmet medical needs\, these needs will evolve over time from improving mortality\, modifying disease progression\, improving quality of life\, burden of the disease\, and potentially curing. \n\n\n\nBringing together multiple stakeholder groups\, including patients and industry\, the 2022 Patient BioForum is an opportunity to listen to patients’ understandings and experiences with unmet medical needs and facilitate progress towards a common understanding on unmet medical needs. \n\n\n\n \n\n\n\nSpeakers \n\n\n\n\nJoelle Khraiche\, EuropaBio\, Patient BioForum co-chair\n\n\n\n\n\nAnca Toma\, EPF\, Patient BioForum co-chair\n\n\n\n\n\nTobias S. Hagedorn\, Secretary of European Society for Phenylketonuria (ESPKU) and Managing Director of DIG PKU Germany\n\n\n\n\n\nPedro Franco\, Director Europe for Global Regulatory & Scientific Policy at Merck and Chair of EuropaBio’s OMP WG\n\n\n\n\nModerator \n\n\n\n\nAdrien Samson\, Healthcare Biotechnology Manager\, EuropaBio\n\n\n\n\n\nInvitation Only Event URL:https://www.europabio.org/event/europabio-patient-bioforum-2022-toward-a-common-understanding-of-unmet-medical-needseuropabio-patient-bioforum-2022/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Patient-BioForum-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20221130T083000 DTEND;TZID=Europe/Brussels:20221130T094500 DTSTAMP:20260726T174257 CREATED:20221103T154442Z LAST-MODIFIED:20221114T101045Z UID:5462-1669797000-1669801500@www.europabio.org SUMMARY:EFIB 2022 Vilnius Statement wider launch DESCRIPTION:Industrial Biotechnology for a sustainable society: a focus for 2023 and beyond Industrial biotechnology and biomanufacturing are recognised as being part of the response to some of today’s pressing global challenges. Delivering on EU Green Deal objectives whilst strengthening resilience and independence of European industries is increasingly critical.  \n\n\n\nThe inaugural EFIB Statement of October 2021 created a baseline for industrial biotechnology and bioeconomy vision in policy\, regulatory and landscape development. The EuropaBio’s EFIB Vilnius Statement of 2022 evolves to address this long-term vision and ambition within the context of challenges and needs over the next 12 months.  \n\n\n\nWe invite you to join us for a discussion on the role and potential of enabling technologies in the EU green transition\, with a focus on priorities for the shorter term and building up to the longer term.   \n\n\n\n \n\n\n\n\nInvitation Only Event URL:https://www.europabio.org/event/efib-2022-vilnius-statement-wider-launch/ CATEGORIES:EFIB,EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/11/Vilnius-Statement-Event-600-×-260px-1-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20220929T140000 DTEND;TZID=Europe/Brussels:20220929T150000 DTSTAMP:20260726T174257 CREATED:20220830T122553Z LAST-MODIFIED:20220922T103100Z UID:5064-1664460000-1664463600@www.europabio.org SUMMARY:European Biotech Week 2022: At the cutting edge of biotechnology for cardiovascular diseases: A World Heart Day special edition webinar DESCRIPTION:Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients\, both in terms of innovative treatments\, but also via use of innovative prevention\, screening\, and testing measures. \n\n\n\nDuring this webinar\, which marks World Heart Day\, speakers will discuss how biomarker testing for genetically inherited risk factors for cardiovascular diseases is opening up new frontiers in healthcare\, and saving lives across the world. \n\n\n\nFeaturing speakers from the patient community\, research and academia\, and industry\, the conversation will also address the need to translate guidelines into practice\, and will end with an interactive Q&A. \n\n\n\nSpeakers: \n\n\n\nMarius Geanta\, Trustee and the Chair of the Policy Advisory Committee\, FH EuropeLena Lymperopoulou\, Global Policy Head Therapeutic Area Cardiovascular\, NovartisFlorian Kronenberg\, Full Professor and Head of the Institute of Genetic Epidemiology\, Medical University of InnsbruckJamie Wilkinson\, Healthcare Biotechnology Director\, EuropaBio\n\n\n\n\nREGISTER NOW URL:https://www.europabio.org/event/european-biotech-week-2022-hc/ CATEGORIES:Biotech Week,EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-HC.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20220927T140000 DTEND;TZID=Europe/Brussels:20220927T150000 DTSTAMP:20260726T174257 CREATED:20220830T105859Z LAST-MODIFIED:20220914T134233Z UID:5054-1664287200-1664290800@www.europabio.org SUMMARY:European Biotech Week 2022: Innovative technologies in the EU green transition – spotlight on industrial biotechnology DESCRIPTION:Industrial Biotechnology-derived products offer significant potential for contributing to overcoming many EU socio-economic and environmental challenges. It is not a new sector. On the contrary\, for thousands of years the power of microbes has been harnessed in food production and beverages. In the past century\, the applications for IB have expanded greatly with IB now providing living microorganisms and fermentation products that are used in sectors as diverse as food and feed\, agriculture\, detergents\, paper and pulp\, textiles\, fuels\, bioenergy\, and specialty chemicals. \n\n\n\nResearch and innovation are key drivers to accelerate the green transition. Indeed\, the EU Green Deal notes that “New technologies\, sustainable solutions and disruptive innovation are critical to achieve the objectives of the European Green Deal”. In this context\, a range of solutions will be needed. Alternatives to fossil-based products\, improved resource efficiency of industrial processes\, innovative food and feed are all targets where industrial biotechnology and bioeconomy innovation can deliver. \n\n\n\nThis webinar will discuss innovative solutions that can contribute towards the green transition\, with a focus on industrial biotechnology. It will zoom in on products of IB and their benefits and challenges\, also linking to the EU GMO regulatory framework and recent developments on new genomic techniques. \n\n\n\nSpeakers: \n\n\n\nMarc Leclerc\, Senior Regulatory Affairs Advisor\, NovozymesRachel Melnick\, Senior Scientific Program Manager\, Agriculture & Food Systems InstituteHans Genee\, Co-Founder and CSO\, Biosyntia\n\n\n\n\nREGISTER NOW URL:https://www.europabio.org/event/european-biotech-week-2022-ib/ CATEGORIES:Biotech Week,EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Europabio-IB.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20220926T140000 DTEND;TZID=Europe/Brussels:20220926T151500 DTSTAMP:20260726T174257 CREATED:20220830T121819Z LAST-MODIFIED:20220923T072206Z UID:5060-1664200800-1664205300@www.europabio.org SUMMARY:European Biotech Week 2022: Biotechnology for society\, sustainability and economies – transformative science for a changing world DESCRIPTION:The 2022 European Biotech Week from EuropaBio opens with a look at how biotechnology is at the centre of Europe’s transformation to a healthy\, sustainable and competitive economy and society. \n\n\n\nJoin our Board Members from across Europe’s biotechnology spectrum to learn about biotech in action and its benefits in our every day lives\, as well as how it supports employment\, economic development and Europe’s place in the world. \n\n\n\nSpeakers: \n\n\n\nPatricia Malarkey\, Global Chief Innovation Officer\, DSMStefan Buchholz\, Senior VP R&D Nutrition and Care\, EvonikTom Bols\, Head of Government Affairs and Patient Advocacy\, PTC TherapeuticsAnnemeik Verkamman\, Managing Director\, HollandBio\n\n\n\n\nREGISTER NOW URL:https://www.europabio.org/event/european-biotech-week-2022-biotechnology-for-society-sustainability-and-economies-transformative-science-for-a-changing-world/ CATEGORIES:Biotech Week,EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2022/09/Events-Template-600-×-200px.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20220602T150000 DTEND;TZID=Europe/Brussels:20220602T161500 DTSTAMP:20260726T174257 CREATED:20220510T072627Z LAST-MODIFIED:20220517T120255Z UID:4513-1654182000-1654186500@www.europabio.org SUMMARY:Rare Conversations 2022! DESCRIPTION:Managing uncertainties in rare disease innovation\n\n\n\n\n\nJoins us for the new episode of Rare Conversations 2022! \n\n\n\nThe second episode of Rare Conversations 2022 will build on the previous Conversation about game-changing opportunities in rare disease R&D. In the first episode\, different experts convened on the existence of opportunities in rare diseases\, that still face obstacles that need to be addressed. This event is meant to discuss and propose solutions on: “Managing uncertainties in rare disease innovation” URL:https://www.europabio.org/event/rare-conversations-2022-2/ CATEGORIES:EuropaBio,External,Healthcare Biotech ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2022/05/Event-Banners-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20211213T140000 DTEND;TZID=Europe/Brussels:20211213T150000 DTSTAMP:20260726T174257 CREATED:20211116T143909Z LAST-MODIFIED:20211216T093602Z UID:3429-1639404000-1639407600@www.europabio.org SUMMARY:EuropaBio 25th Anniversary | mRNA: A voyage of discovery and celebration DESCRIPTION:The existence of messenger(m) RNA was hypothesized early in the days of DNA breakthroughs in the 1960s\, and research from the 1990s started to reveal its potential as a therapeutic tool. \n\n\n\nmRNA became a household name in 2020 and 2021 as arguably the most important global breakthrough of recent years\, with its ability to create a specific proteins underpinning vaccine development in response to Covid-19.EuropaBio is delighted to host the final event of its 25th Anniversary programme with a focus on the story of mRNA. Its first steps into commercial development\, challenges to bring a vaccine to millions of people and life beyond Covid – the destination for mRNA in oncology and other significant health applications. \n\n\n\nWe bring together protagonists from across the spectrum\, including:• Ingmar Hoerr\, CureVac Founder and holder of the first patents associated with mRNA• Stephen Lockhart\, Head of EU/AP Vaccines Clinical R&D at Pfizer• Dhaval Patel\, Senior Manager\, Manufacturing & Technology\, Catalent Biologic URL:https://www.europabio.org/event/europabio-25th-anniversary-mrna-a-voyage-of-discovery-and-celebration/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/Event-Banners-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20211130T140000 DTEND;TZID=Europe/Brussels:20211130T151500 DTSTAMP:20260726T174257 CREATED:20211103T141708Z LAST-MODIFIED:20211119T105146Z UID:3401-1638280800-1638285300@www.europabio.org SUMMARY:EFIB 2021 | Vienna Statement Launch DESCRIPTION:The ‘EFIB 2021 Vienna Statement’ marked the launch of an annual call to action from EuropaBio members\, with policy asks and actions critical in the short term for Europe’s delivery of a bioeconomy. \n\n\n\nDeveloped through 2021 and published at EFIB in Vienna\, the statement includes:• Next generation Europe: An urgent call to action• Industrial biotechnology: Proving its value to society\, environment and economy• The clock is ticking for European climate and competitive ambitions• Time is now – EFIB Vienna Statement requests for modernisation of regulation and policy\, Education and awareness and financing innovation \n\n\n\nModerator: \n\n\n\n• Dr Claire Skentelbery\, Director General\, EuropaBio \n\n\n\nSpeakers: \n\n\n\n• Stefan Buchholz\, Senior Vice President R&D Nutrition & Care\, Evonik \n\n\n\n• Elke Duwenig\,  Senior Biotechnology Expert Regulatory / Public & Government Affairs\, Nutrition & Health\, BASF \n\n\n\n• Jim Philp\, Science and Technology Analyst\, OECD \n\n\n\n• Video message by Simone Schmiedtbauer\, Member of the European Parliament\, Group of the European People’s Party\, Austria \n• Video message by Virginijus Sinkevičius\, European Commissioner for Environment\, Oceans and Fisheries \n\n\n\nWe invite you now to join us for the wider launch of the EFIB Vienna Statement – to set the challenge for Europe and discuss what this means for policy\, regulation\, investment and innovation. \n\n\n\nJoin us on 30 November at 14:00 CET and be part of the conversation in the 12 months until the next EFIB conference in Vilnius\, Lithuania\, October 2022. \n\n\n\n\nRegister Here URL:https://www.europabio.org/event/efib-2021-vienna-statement-launch/ CATEGORIES:EFIB,EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/11/Event-Banners-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20211025T130000 DTEND;TZID=Europe/Brussels:20211025T141500 DTSTAMP:20260726T174257 CREATED:20210916T104948Z LAST-MODIFIED:20211008T103436Z UID:3115-1635166800-1635171300@www.europabio.org SUMMARY:EuropaBio 25th Anniversary | Healthy planet\, Healthy people DESCRIPTION:At the time of the 25th Anniversary of EuropaBio\, we would like to look to the future and the green transition that will shape healthcare for us all. \n\n\n\nThis open webinar aims at kicking off the discussion on pathway for green transition in the biopharmaceutical ecosystem. This biopharmaceutical ecosystem has a complex and resource intensive profile\, from research\, to manufacture through to use and disposal of highly regulated therapeutics. \n\n\n\nChange is Now\, with companies investing in long term product and process design for carbon neutrality and circularity.  Join us to hear from pharma\, sustainable pharmaceutical engineering\, policy makers\, consumers and the European Commission on the priorities\, actions and outcomes to ensure that healthy people go hand in hand with a healthy planet. \n\n\n\nModerator: \n\n\n\nDr Claire Skentelbery\, Director General\, EuropaBio\n\n\n\nSpeakers: \n\n\n\nCarmen Laplaza\, Head of Unit\, Health Innovations and Ecosystems\, DG Research and Innovation\n\n\n\nMontserrat Montaner\, Chief Sustainability Officer\, Novartis\n\n\n\nJutta Paulus\, Member of the European Parliament\, Group of the Greens\, Germany\n\n\n\nDr Wouter De Soete\, Manager Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing\, University of Ghent\n\n\n\nKristin Schreiber\, Director\, Directorate Ecosystems: Chemicals\, Food\, Retail\, Health\, DG Grow\, European Commission\n\n\n\n\n\nREGISTER HERE URL:https://www.europabio.org/event/europabio-25th-anniversary-healthy-planet-healthy-people/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/09/Event-Banners-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20211019T110000 DTEND;TZID=Europe/Brussels:20211019T123000 DTSTAMP:20260726T174257 CREATED:20210929T082422Z LAST-MODIFIED:20211013T123534Z UID:3221-1634641200-1634646600@www.europabio.org SUMMARY:EuropaBio Patient Bio-Forum | European Reference Networks: challenges\, achievements and opportunities DESCRIPTION:EuropaBio\, the European Association for Bioindustries\, is proud to continue our platform for engaging patient and industry alike on pertinent healthcare debates: the Patient Bio-Forum. In this edition the focus will be on the impact of European Reference Networks (ERNs). \n\n\n\nWith an aim to facilitate discussion between patients and medical professionals across the EU\, ERNs tackle rare disease head on. Creating a pooled\, virtually accessible network of experts\, ERNs demonstrate the power of collaboration in diagnosis complex and rare diseases. With the first ERNs having started in 2017\, we anticipate a periodic evaluation during 2022/23. Similarly\, this year the Commission have undertaken an evaluation of the Cross-border Healthcare Directive which establishes the legal basis of ERNs. \n\n\n\nAgainst a backdrop of societal change\, the EuropaBio Patient Bio-Forum convenes this October with a panel of experts representing patient\, industry\, EU and Member State perspectives on the challenges\, achievements and opportunities the ERNs present. \n\n\n\n\n\n\n\nAGENDA \n\n\n\nWelcome and introduction (5 mins) \n\n\n\nNicola Bedlington (Moderator)\n\n\n\nPanel Discussion (45 mins) \n\n\n\nIngunn Westerheim\, President\, OIFE – Osteogenesis Imperfecta Federation Europe;Dr. Birute Tumienė\, clinical geneticist at the Centre for Medical Genetics and the Coordinator for Competence Centres in Vilnius University Hospital Santaros Klinikos\, ERN Board Member on behald of LithuaniaDr. Jose A. Valverde\, Policy Officer\, Unit B.3 – European Reference Networks and Digital Health\, DG SANTE\, European Commission;Assoc. Prof. Dr Till Voigtländer\, Department of Neuropathology and Neurochemistry University of Vienna\, Eurordis Black Pearl Awardee 2019Dirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets\, Pfizer\n\n\n\nBiobreak/Slido Poll (5 mins) \n\n\n\nModerated Q&A (35 mins) \n\n\n\nFrom the audience\, submitted via chat function.\n\n\n\nClosing remarks URL:https://www.europabio.org/event/europabio-patient-bio-forum-european-research-networks-challenges-achievements-and-opportunities/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/10/Event-Banners-28.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20211005T100000 DTEND;TZID=Europe/Brussels:20211007T190000 DTSTAMP:20260726T174257 CREATED:20210127T070638Z LAST-MODIFIED:20210526T082935Z UID:820-1633428000-1633633200@www.europabio.org SUMMARY:European Forum for Industrial Biotechnology & the Bioeconomy (EFIB) DESCRIPTION:Save the date for this 14th edition!EFIB is the market leading annual event in Europe for Industrial Biotechnology and the Bioeconomy. Visit the dedicated website to secure your place today. \n\n\n\n\n\nhttps://efibforum.com/ URL:https://www.europabio.org/event/european-forum-for-industrial-biotechnology-the-bioeconomy-efib/ LOCATION:Vienna (Austria)\, Vienna\, Austria CATEGORIES:EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-EFIB.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210927T080000 DTEND;TZID=Europe/Brussels:20211003T080000 DTSTAMP:20260726T174257 CREATED:20210128T134240Z LAST-MODIFIED:20210610T122254Z UID:948-1632729600-1633248000@www.europabio.org SUMMARY:European Biotech Week 2021 DESCRIPTION:The European Biotech Week celebrates biotechnology\, an innovative and vibrant sector launched by the discovery of the DNA molecule back in 1953. The first European Biotech Week that took place in 2013 marked the 60th anniversary of this pivotal moment in history. \n \n  URL:https://www.europabio.org/event/european-biotech-week-2021/ CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/European-Biotech-Week-Event-Banner-.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210921T143000 DTEND;TZID=Europe/Brussels:20210921T153000 DTSTAMP:20260726T174257 CREATED:20210831T112430Z LAST-MODIFIED:20210922T093101Z UID:3028-1632234600-1632238200@www.europabio.org SUMMARY:EFIB Pre-event webinar DESCRIPTION:Sustainability in industrial biotech innovations: life cycle assessment and beyond \n\n\n\nSponsored by DSM\n\n\n\n \n\n\n\n\n\nGet ready for EFIB 2021 by attending the kick-off webinar “Sustainability in Industrial biotech innovations: Life Cycle Assessment and beyond”\, which will take place on Tuesday 21 September 2021 from 14.30 – 15.30 CET. \n\n\n\nSustainability is the drive and purpose behind most industrial biotech innovations. But how to incorporate it in the innovation process? How to assess it\, measure it\, and use it for decision making? During this webinar we will explore: \n\n\n\n• How well-established tools like Life Cycle Assessment are being used in industrial biotech innovations \n\n\n\n• What are novel tools and methodologies relevant for the sustainability assessment of industrial biotech \n\n\n\n• How corporates\, start-ups and academia use these tools in their innovation process \n\n\n\nThis kick-off webinar by EuropaBio is co-hosted by Planet B.io\, the open innovation hub for industrial biotechnology\, located at the Biotech Campus Delft in The Netherlands. \n\n\n\nModerator: \n\n\n\n • Maria Cuellar-Soares | S&T Officer\, Planet B.io \n\n\n\nSpeakers: \n\n\n\n • Ulla Létinois | Senior Scientist\, Sustainable Chemistry\, DSM \n\n\n\n • Yang Xiang | Senior Corporate LCA Expert\, DSM \n\n\n\n • Cristina Prat | Co-founder\, FUL Foods \n\n\n\n • John Posada | Assistant Professor in Biotechnology and Society\, TU Delft \n\n\n\n\nSlides\n\n\n\n\nParticipation for this webinar is free of charge\, but registration is required. \n\n\n\n\nREGISTER HERE URL:https://www.europabio.org/event/efib-pre-event-webinar/ CATEGORIES:EFIB ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/08/Event-Banners.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210907T160000 DTEND;TZID=Europe/Brussels:20210907T170000 DTSTAMP:20260726T174257 CREATED:20210715T095059Z LAST-MODIFIED:20210903T072658Z UID:2936-1631030400-1631034000@www.europabio.org SUMMARY:Treatment without borders: the EU case for equitable patient access to advanced therapies DESCRIPTION:The EU Pharmaceutical Strategy is looking to improve patients’ access to therapies for challenging and rare conditions. The EU legislation on cross-border healthcare is an important instrument to ensure patient access to the best available care. There is an urgent need to revise this legislation to enable EU patients to access novel advanced therapies and medicines for rare diseases when these are not available in their home country. \n\n\n\nEuropaBio’s Advanced Therapies Series continues with a virtual discussion on avenues for enhancing the access of EU patients to novel biotechnology-derived treatments on September 7\, 2021\, from 16h00 to 17h00 CET. \n\n\n\nA patient who is also actively engaged in patient advocacy will explain the value of advanced therapies for rare disease patients and the key challenges they encounter when accessing treatments outside their home countries. \n\n\n\nA panel of EU\, national\, and industry representatives will attempt to put forward solutions for securing equitable access to both specialised centres and to treatment for all EU patients in need. Among others\, they will seek to advise on how to tackle the following challenges: some treatment centres being less interested to treat cross-border patients\, the need for experience and expertise in rare diseases\, approval process and time for cross-border treatment\, lack of knowledge or experience of healthcare providers in requesting reimbursement for cross-border treatments\, difficulties in approving advanced therapy applications if not reimbursed in the home country\, etc. \n\n\n\nModerator \n\n\n\nBernard Grimm\, Healthcare Biotech Director\, EuropaBio \n\n\n\nSpeakers \n\n\n\nJana Popova\, Executive Committee Member of the European Alliance of Neuromuscular Disorders Associations & EUPATI Patient Engagement Training Coordinator \n\n\n\nBrieuc Van Damme\, Director-General Healthcare\, RIZIV-INAMI \n\n\n\nMartin Dorazil\, Deputy Head of Unit\, DG Health\, European Commission \n\n\n\nDirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets\, Pfizer \n\n\n\nIrina Grossenbacher\, Region Europe Patient Access Director\, Novartis Rare Diseases \n\n\n\nTomislav Sokol\, Member of the European Parliament\, EPP\, Croatia URL:https://www.europabio.org/event/treatment-without-borders-the-eu-case-for-equitable-patient-access-to-advanced-therapies/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/07/NL-Size-28.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210630T121500 DTEND;TZID=Europe/Brussels:20210630T134500 DTSTAMP:20260726T174257 CREATED:20210609T145626Z LAST-MODIFIED:20210611T110808Z UID:2648-1625055300-1625060700@www.europabio.org SUMMARY:Changing Global Ambitions for Biotechnology Innovation: Implications and Drivers for Europe DESCRIPTION: \nEuropaBio hosts a member-only discussion session looking at ambitions for innovation and business in China\, and how this impacts both the EU and US. We are delighted to welcome McKinsey’s China office to the meeting\, where they will present an inside look at changing Chinese ambitions for industrial growth from innovation.\n \nMember discussion then focuses on how Europe can deliver its own ambitions in a world where changes beyond its borders will influence success\, and how it needs to develop a strong and realistic economic vision for technology from companies and governments.\n \nEuropaBio looks forward to an interesting cross-sector debate amongst Members on the long-term future of Europe as a global competitor and economic performer within the technology space\, within profound economic changes world-wide.\n \nAll members are eligible to attend and should contact EuropaBio (m.cilia@europabio.org) if they have not yet received an invitation. URL:https://www.europabio.org/event/changing-global-ambitions-for-biotechnology-innovation-implications-and-drivers-for-europ/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/06/Event-Banners-25.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210603T140000 DTEND;TZID=Europe/Brussels:20210603T150000 DTSTAMP:20260726T174257 CREATED:20210315T132511Z LAST-MODIFIED:20210602T083815Z UID:1616-1622728800-1622732400@www.europabio.org SUMMARY:EU Healthcare Biotech Policy Priorities for SMEs DESCRIPTION:Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing revision of the basic pharmaceutical legislation and of regulations for medicines for rare and paediatric diseases\, SMEs should be planning how they build and grow their businesses\, whether within the EU or outside. \n\n\n\nAbout the EuropaBio SME Platform \n\n\n\nThe SME platform is a community of SMEs across all sectors in Europe\, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders. \n\n\n\n  \n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n  URL:https://www.europabio.org/event/eu-healthcare-biotech-policy-priorities-for-smes/ CATEGORIES:EuropaBio,Healthcare Biotech,SME Platform ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-9-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210527T130000 DTEND;TZID=Europe/Brussels:20210527T143000 DTSTAMP:20260726T174257 CREATED:20210511T134921Z LAST-MODIFIED:20210528T100244Z UID:2445-1622120400-1622125800@www.europabio.org SUMMARY:EFIB 2021 Kick-Off Webinar - How to accelerate biotech innovation for a sustainable future DESCRIPTION:Get ready for EFIB 2021 by joining our launch webinar “How to accelerate biotech innovation for a sustainable future”. \n\n\n\n EuropaBio is pleased to announce this kick-off webinar\, co-hosted by DSM and Planet B.io\, both located at the Biotech Campus Delft. The webinar will feature industry\, start-up\, and financing perspectives on the European biotechnology innovation ecosystem.  \n\n\n\nIt will provide insights on recent developments in the field\, discuss cooperation in the field and have an outlook on what to expect at EFIB 2021 in Vienna this year.  \n\n\n\nSpeakers:\n\n\n\n– Claire Skentelbery – General Director\, EuropaBio– Cindy Gerhardt – Managing Director\, Planet-B.io at the Biotech Campus Delft– Rob van der Meij – Partner\, Capricorn Partners– Amadeus Driando Ahnan-Winarno – Co-Founder & Head of Technology\, Better Nature \nYou can watch the video recording here\, or download the speakers’ presentations here. \n\n\n\n\n\n\n\n\n\n\nREGISTER HERE\n\n\n\n\n\n\n\n\n\n\n  URL:https://www.europabio.org/event/efib-2021-kick-off-webinar-how-to-accelerate-biotech-innovation-for-a-sustainable-future/ CATEGORIES:EuropaBio,Industrial Biotech ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/05/Event-Banners-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210520T140000 DTEND;TZID=Europe/Brussels:20210520T150000 DTSTAMP:20260726T174257 CREATED:20210421T071455Z LAST-MODIFIED:20210517T090546Z UID:2157-1621519200-1621522800@www.europabio.org SUMMARY:Then and Now – Delivering a Successful Therapeutic to Patients DESCRIPTION:In today’s whirlwind of diagnostics\, vaccines and therapeutics\, we take a step back and look at how the world of development and manufacturing of biologics has evolved over the last 25 years\, bringing together EuropaBio Members and 25th Anniversary Sponsor\, Catalent.We look back at changing experience from the last quarter of a century in the pathway to patients\, plus how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing. Hear expert presentations from EuropaBio Members and Catalent Biologics\, before a detailed Q&A session with the audience on all aspects of developing a successful biologic in 2021. \n\n\n\nAspects to be discussed include: \n\n\n\nWhat trends are driving growth in the pharma industry\, and how are next generation therapies addressing previously unmet needs?As advanced technologies travel through the pipeline\, how are pharma companies\, CDMOs and other partners able meet their complex and novel requirements?In a global world\, how do you embrace and integrate skills and capacity from multiple sites\, often in different continents?As complex\, advanced medicines become reality\, how do you work with regulators from the earliest stages of pre-clinical development to enable a smooth pathway to clinic and market?\n\n\n\nFEATURED SPEAKERBehzad Mahdavi\, Ph.D.​Vice President of Open Innovation\, Biologics\, Cell and Gene Therapy \n\n\n\nMartine Lewi\,​Scientific Director\, Janssen R&D/Clinical Innovation \n\n\n\n \n\n\n\nWith over 20 years’ experience in developing and implementing impactful growth strategies in the biopharmaceutical industries\, Dr. Mahdavi joined Catalent in 2020 after a 13-year career at Lonza\, where he held the role of Vice President Strategic Innovation & Alliances\, and various board-level positions at other innovative companies. Prior to joining Lonza\, he was Chief Executive Officer of SAM Electron Technologies\, a venture capital-backed company in the life sciences field. He holds a doctorate in chemistry from the University of Sherbrooke\, Canada\, and also has a master’s in business administration from the University of Quebec in Montreal. \n\n\n\nJoin this webinar co-organised by Catalent and EuropaBio in the framework of EuropaBio 25th Anniversary and take part to the celebrations! \n\n\n\n \n\n\n\n \n\n\n\n\nREGISTER HERE URL:https://www.europabio.org/event/then-and-now-delivering-a-successful-therapeutic-to-patients/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/04/Catalent-Webinar.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210518T103000 DTEND;TZID=Europe/Brussels:20210518T143000 DTSTAMP:20260726T174257 CREATED:20210324T082247Z LAST-MODIFIED:20210427T094258Z UID:1606-1621333800-1621348200@www.europabio.org SUMMARY:EuropaBio Patient BioForum: Advancing patient access to innovative treatments DESCRIPTION:2021 is set to be another landmark year in the area of health. It is hoped to not only relieve the burden of the COVID-19 pandemic on EU patients and healthcare systems\, but also let the health community advance the great number of other priorities there are. In the EU\, 2021 is set to give a start to the implementation of the European Health Union and the related objectives of the new EU Pharmaceutical Strategy. Among these\, the EU health community is looking to improve patients’ access to therapies for challenging and rare conditions. \n\n\n\nThis meeting of EuropaBio’s Patient BioForum will discuss avenues for enhancing the access of EU patients to novel biotechnology-derived treatments in two sessions: \n\n\n\nMorning session – 10:30-12:00 CET\n\n\n\nPharmaceutical Strategy implementation for continued innovation and delivery in the area of rare and paediatric diseases. \n\n\n\nThe European Commission is discussing on the calibration of incentives for investing in the development of medicines for rare and paediatric diseases both with Member States and stakeholders. We invite the BioForum members to exchange proposals for informing this important debate on several key points\, such as criteria for defining unmet need and incentivising innovation in such areas\, etc. \n\n\n\nAfternoon session – 13:00-14:30 CET\n\n\n\nImproving patient access across borders \n\n\n\nThe EU Directive on cross-border healthcare is an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases. Well-functioning EU cross-border healthcare legislation can ensure patients have access to specialised treatments and novel therapies when these are not available in their home country. \n\n\n\nThe exchange between guest speakers and BioForum members is aimed to result in the post-meeting release of policy recommendations for how patient access can be advanced in the EU in the context of its new Pharmaceutical Strategy. \n\n\n\nWe very much look forward to your active participation on 18 May 2021.  \n\n\n\n \n\n\n\nVIRTUAL EVENT URL:https://www.europabio.org/event/europabio-patient-bioforum-advancing-patient-access-to-innovative-treatments/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210511T120000 DTEND;TZID=Europe/Brussels:20210511T130000 DTSTAMP:20260726T174257 CREATED:20210312T082225Z LAST-MODIFIED:20210506T121206Z UID:1571-1620734400-1620738000@www.europabio.org SUMMARY:Taking health up a gear: value of advanced therapies DESCRIPTION:Advanced therapies have ground-breaking therapeutic potential\, particularly in disease areas where there is an unmet medical need and available therapeutic options are absent or inadequate. These therapies can bring the possibility of a cure to life-threatening conditions with a one-off treatment\, thereby changing the paradigm of providing health and care to patients suffering serious\, rare or complex diseases. \n\n\n\nA breakthrough innovator in the area of rare diseases will explain the cutting-edge science behind gene therapies\, why they are considered so transformative\, and what promise they hold to addressing unmet patient needs. \n\n\n\nA leading developer of the most innovative cancer treatments – CAR-T cell-based therapies will explain the changing paradigm of providing health for cancer patients and how innovation will help achieve the objectives of Europe’s Beating Cancer Plan. \n\n\n\nThe webinar will also engage policy makers reflecting live on how EU policies can truly harness the ground-breaking potential of advanced therapies. \n\n\n\nSpeakers \n\n\n\nSara Cerdas MEP\, BECA \n\n\n\nDick Sundh\, Head of ACE (Australia\, Canada & Europe) at Kite Pharma\, a Gilead Company \n\n\n\nDirk Vander Mijnsbrugge\, Vice President Medical Affairs Lead Rare Diseases International Developed Markets at Pfizer \n\n\n\nSimone Boselli\, Public Affairs Director at EURORDIS  \n\n\n\n \n\n\n\nAbout EuropaBio Advanced Therapies Series: \n\n\n\nThe EuropaBio Advanced Therapies series of events\, interviews\, and publications will engage policymakers\, regulators\, patients and their representatives\, developers\, and all relevant stakeholders to discuss how innovation in gene- and cell-based medicine can bring a transformative value for patients. \n\n\n\nThroughout 2021\, we invite you to join us on a journey of exploring the tremendous potential of advanced therapies by discussing the new treatment paradigms\, the future of research and development in this fast-moving space of bio-science\, as well as debating recommendations for improving the access of patients to these ground-breaking treatments and supporting advanced manufacturing\, to name a few. \n\n\n\nVIRTUAL EVENT \n\n\n\n\nREGISTER HERE URL:https://www.europabio.org/event/taking-health-medicine-up-a-gear-value-of-advanced-therapies/ CATEGORIES:EuropaBio,Healthcare Biotech ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-10.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Brussels:20210510T150000 DTEND;TZID=Europe/Brussels:20210510T180000 DTSTAMP:20260726T174257 CREATED:20210316T153010Z LAST-MODIFIED:20210511T074409Z UID:1593-1620658800-1620669600@www.europabio.org SUMMARY:Building on biotechnology: From vaccines to economic growth for Europe DESCRIPTION:EuropaBio National Associations Council\n\n\n\nSummit 2021 – Portugal \n\n\n\n \n\n\n\n\n\n\n\n\n\nEuropaBio’s National Associations Council (NAC) is a platform that brings together all EuropaBio’s National Associations and helps to ensure coordination of EuropaBio actions throughout Europe. The NAC represents biotechnology priorities across Europe’s Member and partner countries\, working together to build long term economic and societal benefit from biotechnology across sectors. \n\n\n\nIn 2021\, the NAC is proud to host its first Summit focussed on priorities for commercial biotechnology development\, delivering the Industrial Strategy within national and European ecosystems. \n\n\n\nThe NAC summit on May 10 will address how we learn from the COVID-19 response\, to enable full societal and economic benefit from biotechnology in the future across sectors. Rapid technology development pathways\, including partnering\, investment and approvals\, created in response to the pandemic have created new\, faster routes to market. Although this was a unique scale and speed for vaccine development\, it shows that biotech can perform quickly and strongly to address unmet issues in healthcare and sustainable development\, creating a solution and also supporting economic recovery across Europe. \n\n\n\nThe EuropaBio NAC Summit is held during the Portuguese Presidency of the Council of EU and organized in collaboration with P-BIO. The outcomes from the Summit will include a EuropaBio NAC Position on building economic pathways from biotech post-Covid with the role of aligned and ambitious national policies and actions. \n\n\n\n \n\n\n\nAgenda\n\n\n\n15:00: Welcome – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n15:05: Opening remarks – Manuel Heitor\, Minister of Science\, Technology and Higher Education\, Portugal \n\n\n\n15:15: A European ambition in a competitive global landscape. \n\n\n\nWhere biotech and economic ambitions sit within European and global strategies – Claire Skentelbery\, Director General\, EuropaBio \n\n\n\n \n\n\n\n15:30: Session 1 – A new biotechnology ecosystem in Europe \n\n\n\n\nCompanies active in the current response to Covid-19 share how they have built vital collaborations across the biotech-pharma spectrum to deliver breakthrough vaccine technologies to patients at unprecedented speed\, plus how they envision future potential. \n\n\n\n15:30: Economic development driven by Biotech – the Portugal perspective: David Malta\, Founding CEO\, LiMM Therapeutics \n\n\n\n15:45: Developing bio-manufacturing partnerships – Elke Grooten\, Head of EU Relations\, Novartis \n\n\n\n16:00: Pharma-SME collaboration: from innovation to patient\, a global journey – Sinan Atlig\, Regional President IDM\, Vaccines Pfizer \n\n\n\n16:15: Break \n\n\n\n\n16:30: Session 2 – Looking to the future – speed and strength from biotech \n\n\n\nSMEs driving next generation biotechnology present the pathway and challenges to success and highlight what Europe needs to achieve.  EuropaBio National Associations will then discuss the critical framework needed to build further from national and European ecosystem advances from Covid\, accelerating biotech contribution to Europe’s economic development. \n\n\n\nSME drivers \n\n\n\n16:30: The future of vaccines – Bruno Santos\, Co-Founder and CEO\, IMMUNETHEP \n\n\n\n16:40: Reaching all patients for immunity – Kim Kjøller\, CEO\, UNION Therapeutics \n\n\n\nBuilding European strengths \n\n\n\n16:50: Discussion Panel – Associations from across Europe plus audience contributions \n\n\n\nModerator: Claire Skentelbery \n\n\n\nPanellists: \n\n\n\n– Agne Vaitkeviciene\, Executive Director\, Lithuanian Biotechnology Association \n\n\n\n– Chloe Evans\, Market Research Manager & International Relations\, France Biotech \n\n\n\n– Simão Soares\, President\, P-BIO \n\n\n\n– Hanne Mette Dyrlie Kristensen\, CEO\, The Life Science Cluster (Norway) \n\n\n\n18:00: Summary and Close \n\n\n\nVIRTUAL EVENT \n\n\n\n\nREGISTER HERE\n\n\n\n\nWho should attend? \n\n\n\nThe EuropaBio NAC Summit is open and free of charge.  You should attend if you are active within the development of biotechnology ecosystems at national or European levels\, either as a technology stakeholder (academic or industrial) or a facilitator of technology maturation to market and patients (associations\, tech transfer\, investors\, policy makers…). The event will have a strong discussion element and all participants can be actively involved. The event will also develop preparatory statements for delegate feedback plus post-event discussion on the planned NAC Position. \n\n\n\nDownload below the speakers’ presentations: \n\n\n\nEuropaBio-NAC-Summit-10-May-2021-Slides-FINAL-PDFDownload URL:https://www.europabio.org/event/building-on-biotechnology-from-vaccines-to-economic-growth-for-europe/ CATEGORIES:EuropaBio ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-3.png END:VEVENT END:VCALENDAR